Structural diversification and selective inhibition of HDAC3: A comprehensive review of inhibitors and degraders

Key Points

• Selective inhibition of HDAC3 can lead to targeted therapeutic strategies, enhancing treatment outcomes.
• Key evidence shows that multiple structural classes of inhibitors exist, each impacting HDAC3 differently.
• The comprehensive review assesses numerous inhibitors and degraders, offering insights into their mechanisms and efficacy.
• Understanding the structural diversity of HDAC3 inhibitors may pave the way for novel drug designs and better therapeutic approaches.